| Prev Close | 132.07 |
| Day Low/High | 130.19 / 132.39 |
| 52 Wk Low/High | 121.00 / 148.99 |
| Avg Volume | 6.88M |
Johnson & Johnson (JNJ)
130.31
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.66B |
| Market Cap | 350.65B |
| EPS | 5.70 |
| P/E Ratio | 24.46 |
| Div & Yield | 3.80 (2.77%) |
Jim Cramer: I Can't Tell You to Buy This Market
I am urging you to think a little more long-term.
Helmets and Flak Jackets
Unimpressed Equity markets headed lower as the regular Friday trading session extended into it's second and third hours. The way down has been led, not by Adobe , not by Costco , but by Johnson & Johnson . I have been known to make limited attempts ...
Jim Cramer: The Operative Term for This Tape Is Treacherous
Use it to your advantage or don't use it at all.
Jim Cramer: Don't Throw Away These Stocks
It's done without much thought even though their companies are doing amazingly well.
3 Tips for Trading the Fed's More Dovish Stance
Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?
This Black Friday, Any Rally Will Be Light: Market Recon
With all the major indices trading below 50-day moving averages, it would take a big move up to be meaningful.
Pfizer Shares Jump on Monday After Company Signals Higher Price Push
Pfizer pushes higher on price increases.
Bulls Stampeded by Bears as FAANG Stocks Get Trampled
A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.
Tech Selloff Could Work in Favor of Pharmaceutical Stocks
Pharma could be the best parking spot for your money if the market keeps trending downward.
Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Eli Lilly's Elanco Offload Offers Acquisition Flexibility
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Jim Cramer: The Stock Market's Machine Buyers
These are simply programs where some ETFs and handcrafted baskets are overwhelming both sides of the market.
Jim Cramer: An Absence of Negatives Is a Real Positive
This is what the market looks like when the Fed says nothing and the president isn't ranting about something.
Netflix Is Tonight's Big Report: Here's How I Would Play It
This is a battleground stock that has made big moves in both directions on earnings in the past.
Here's How to Play Adobe on Killer Growth Forecast: Market Recon
Adobe released new guidance for the rest of this year and 2019. With 20% growth in the cards, this name is a buy.
Ignore the Misleading Dow Jones Industrial Average
The DJIA is not accurately reflecting what's going on in the market and will cause you to miss broader weakness that has taken hold.
Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?
The answer is plenty, but you can't trade that.
J&J Stock Is Firming Up Nicely, Stay Long
Let's check some updated charts to see if our strategy is still on track.
Considering Several Trading Short Rentals
As many are aware...I am a believer that in a sea of green, stocks that are red are short trading candidates over the very short term. Conversely, in a sea of red, stocks that are green are long trading candidates over the very near term. Following ...
Jim Cramer: This Is a Rotation, Not a Recession
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Why Pay a Premium for Estee Lauder?
EL's stock is up despite a guidance cut.
Jim Cramer: Could Turkey Prove to Be One More Buying Opportunity?
I always say that you should wait until you get an exogenous reason for stocks to come down and then you should pounce.
Buy Johnson & Johnson, Now Poised to Rally
Johnson & Johnson prices finally look ready to move up.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
The 4 Cheapest 'Dividend Kings' to Buy Today
These stocks offer not only terrific histories of dividend increases, but are also trading at reasonable valuations.
Jim Cramer: How to Pick Stocks When the Market Is Flying Blind
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Johnson & Johnson Is a Great Company, But Be Patient
Bulls see a $158 price target, but JNJ needs a rally to $135.28 for a breakout.
